Following a positive interim analysis showing that fractional flow-reserve-guided PCI was superior to optimal medical treatment, an independent Data and Safety Monitoring Board (DSMB) has recommended that patient enrollment in the ongoing FAME II trial be stopped.
Consequently, it passed a law prohibiting auditors from prescribing any particular accounting treatment of the credit--thereby allowing companies to flow the credit through to earnings all at once or amortize it as they pleased.
Jude Medical, Inc. (NYSE:STJ), a global medical device company, announced today that an interim analysis of the FAME II trial has found a highly statistically significant reduction in the need for hospital readmission and urgent revascularization when Fractional Flow Reserve (FFR)-guided assessment was used to direct treatment in patients with coronary artery disease.
The treatment ends with a shiatsu foot massage where pressure is applied to acupuncture points that allow for the better flow of energy throughout the body.